PRMT5 and PRMT7 are required for sDMA modification of Sm proteins. (A) Lysates from mock-treated (lane 1) and PRMT5 (lane 2), PRMT7 (lane 3), MEP50 (lane 4), and SMN (lane 5) siRNA–treated cells were probed with anti-sDMA antibodies SYM10 (top), Y12 (middle), and SYM11 (bottom right). The lysates were probed with tubulin to verify load (bottom left). The open circles represent proteins that require PRMT5, MEP50, and PRMT7 for their methylation. The closed circles represent proteins that require PRMT5 and MEP50 but not PRMT7 for their methylation. The star represents a protein whose methylation status appears unaffected upon the depletion of PRMT5, MEP50, or PRMT7. (B) HeLa cells were treated with siRNAs against PRMT5 (lane 2), PRMT7 (lane 3), or both (lane 4). GFP siRNAs were used as a control (lanes 1–3). Lysates were prepared and analyzed by blotting with the indicated antibodies. (C) HeLa cells were depleted of PRMT5 (lanes 2 and 3). GFP siRNAs were used as a control (lane 1). A FLAG-PRMT7 overexpression construct was transfected into PRMT5-depleted cells (lane 3). Empty vector was transfected as a control (lanes 1 and 2). Lysates were prepared and analyzed by blotting with the indicated antibodies. The asterisk represents a protein that cross reacts with the PRMT7 antibody. (D) 1 μg GST (lanes 1 and 2) or GST-SmD3 C-terminal tail (GST-D3tail; lanes 3 and 4) immobilized on glutathione–Sepharose beads was incubated for 1 h with total HeLa lysates from untreated cells (lanes 1 and 3) or cells treated with MTA (750 μM for 24 h; lanes 2 and 4). The bound proteins were eluted by boiling in SDS buffer and analyzed by blotting using the indicated antibodies.

Coilin is found in nucleolar caps in cells depleted of SMN, PRMT5, or PRMT7. (A) Control cells as well as cells depleted of SMN, PRMT5, or PRMT7 were processed for immunofluoresence using antibodies against coilin (red) and fibrillarin (green). The arrows indicate the nucleolar capping phenotype. The images in A and B represent the maximum projection of a z stack that has been deconvolved. (B) Cells depleted of PRMT5 and PRMT7 were processed for immunofluoresence using antibodies against coilin (red) and SMN (green). PRMT7-depleted cells are shown. Note that the coilin nucleolar caps (arrows) also contain SMN. (C) Cells depleted of SMN, PRMT5, or PRMT7 were scored for the presence of CBs and also for the coilin nucleolar capping phenotype. The results were graphed as a percentage of the mock-treated cells. A total of 200 cells were scored for each treatment condition. Bars, 10 μM.

siRNA treatment of PRMT5, PRMT7, MEP50, and SMN. (A) HeLa cells were transfected with siRNAs targeting PRMT5 (lane 2), PRMT7 (lane 3), MEP50 (lane 4), and SMN (lane 5). As a control, cells were untransfected (mock; lane 1) or transfected with siRNAs against GFP (lane 6). 72 h after transfection, lysates were prepared and probed with the indicated antibodies. (B) The protein levels from three separate experiments were quantified. The protein levels were normalized to tubulin and graphed as a fraction of the mock transfection. Error bars represent SD.

sDMA modification of Sm proteins is required for efficient snRNP biogenesis. (A) HeLa cells stably expressing CFP-SmB were depleted of PRMT5 (lane 3) or PRMT7 (lane 4) using RNAi. Mock-treated cells were used as a control (lanes 1 and 2). 72 h after transfection, the cells were harvested, cytoplasmic fractions were prepared, and CFP-SmB was immunoprecipitated using polyclonal GFP antibodies (lanes 2–4). To verify binding specificity, a control myc antibody was used (lane 1). The level of coprecipitating SMN was examined (top). The immunoprecipitation efficiency was verified using a monoclonal GFP antibody (bottom). (B) Cells treated for 24 h with either 750 μM MTA (lane 3) or DMSO (lanes 1 and 2) were pulse labeled with [³⁵S]methionine and [³⁵S]cysteine for 1 h. Subsequently, complete media was added to the cells for a 30-min chase. The cells were harvested, and snRNPs were immunoprecipitated using anti-TMG antibody–coated beads (lanes 2 and 3). Protein A beads were used to demonstrate binding specificity (lane 1). Representative samples were also probed with the tubulin antibody (bottom) to serve as a loading control. The abundant copurifying U1 snRNP proteins are indicated. (C) Cells depleted of SMN (lane 3), PRMT5 (lane 4), or PRMT7 (lane 5) were used in the pulse-chase assay described in A using similar controls. (D) The precipitated levels of the abundant snRNP proteins from three separate RNAi/snRNP assembly experiments were quantified and graphed as a fraction of the mock transfection. Error bars represent SD. (E) HeLa cells stably expressing CFP-SmB were depleted of SMN (lane 3), PRMT5 (lane 4), or PRMT7 (lane 5). Mock-treated cells were used as a control (lanes 1 and 2). The cells were pulsed with [³²P]orthophosphate for 2 h. The cells were harvested, total lysates were prepared, and CFP-SmB was immunoprecipitated. Protein A beads were used to demonstrate binding specificity (lane 1). The associated snRNAs were extracted and examined by autoradiography.

PRMT5, PRMT7, and SMN depletion affects cytoplasmic snRNP assembly. (A) Cells treated for 24 h with either 750 μM MTA (lanes 2 and 4) or DMSO (lanes 1 and 3) were pulse labeled with ³⁵S as described in Fig. 3 A. The cells were harvested, and nuclear and cytoplasmic fractions were prepared. The snRNPs from each fraction were immunoprecipitated using anti-TMG antibody–coated beads. (B) Cells depleted of SMN (lanes 2 and 6), PRMT5 (lanes 3 and 7), or PRMT7 (lanes 4 and 8) were used in the pulse-chase assay. Mock-treated cells were used as a control (lanes 1 and 5). Binding conditions are the same as in A.